Edwards Lifesciences Corp
EWHealthcareedwardslifesciences.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 4, 2026
Next reportFebruary 8, 2027after close · forecast 0.73 $/share
Revenue
$1.72B
▲ +10.5% vs prior year YoY
Net income
$307.50M
▲ +5.6% vs prior year YoY
EPS
0.53$
▲ +6.0% vs prior year YoY
Net margin
17.9%
▼ -0.8 pp vs prior year YoY
Revenue▲ +10.5%
Margins (% of revenue)GrossOperatingNet
Net income▲ +5.6%
EPS▲ +6.0%
Financial statements
View 10-Q filed November 4, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $1.10B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B | $1.74B | $1.72B | ▲ +10.5% |
| Gross profit | $917.30M | $1.11B | $1.19B | $1.21B | $1.23B | $1.29B | $1.35B | $1.35B | ▲ +11.5% |
| Operating income | $271.50M | $394.80M | $411.20M | $307.10M | $151.10M | $477.60M | $513.20M | $299.10M | ▼ -2.6% |
| Net income | $385.60M | $358.00M | $333.20M | $291.10M | $91.20M | $380.70M | $241.90M | $307.50M | ▲ +5.6% |
| R&D | $241.80M | $254.60M | $276.20M | $280.70M | $267.70M | $263.30M | $278.90M | $281.40M | ▲ +0.2% |
| EPS (diluted) | — | 0.61 $ | 0.56 $ | 0.50 $ | — | 0.66 $ | 0.42 $ | 0.53 $ | ▲ +6.0% |
| Margins (% of revenue) | |||||||||
| Gross | 83.3 % | 78.7 % | 77.5 % | 77.8 % | 78.1 % | 78.0 % | 77.5 % | 78.5 % | ▲ +0.7 pt |
| Operating | 24.7 % | 27.9 % | 26.8 % | 19.8 % | 9.6 % | 29.0 % | 29.5 % | 17.4 % | ▼ -2.3 pt |
| Net | 35.0 % | 25.3 % | 21.7 % | 18.7 % | 5.8 % | 23.1 % | 13.9 % | 17.9 % | ▼ -0.8 pt |
| Balance sheet | |||||||||
| Assets | $13.06B | $13.02B | $13.49B | $13.27B | $13.70B | $13.32B | $13.87B | $14.14B | ▲ +6.6% |
| Liabilities | $2.99B | $2.83B | $2.88B | $3.07B | $3.36B | $2.99B | $3.14B | $3.18B | ▲ +3.8% |
| Equity | $10.06B | $10.19B | $10.61B | $10.21B | $10.34B | $10.33B | $10.72B | $10.96B | ▲ +7.4% |
| Cash | $3.05B | $3.14B | $3.27B | $2.69B | $2.94B | $2.45B | $2.91B | $3.11B | ▲ +15.8% |
| Capital | |||||||||
| Shares outstanding | 587.90M | 586.60M | 587.10M | 580.30M | 580.80M | 575.80M | 576.40M | 575.00M | ▼ -0.9% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.